Lankenau Heart Institute, Part of Main Line Health, 1st in No America to Sign Long-term Strategic Partnership with Philips Utilizing Integrated Cardiovascular Solutions

Unique five-year agreement will help Philadelphia-based health leader integrate and standardize innovative cardiovascular care, helping to deliver on the quadruple aim

Lankenau Heart Institute part of Main Line Health, and Royal Philips today announced they have entered a five-year strategic partnership focused on integrated cardiovascular solutions.

Working together, Philips and Main Line Health will develop an ecosystem of clinically-enabled cardiovascular solutions that will allow Main Line Health to standardize and integrate technology across its network, helping to unlock patient data for better clinical decisions, while optimizing workflows for a better patient and staff experience. In addition, the partnership aims to help Main Line Health drive predictability and consistency in costs, as well as focus on clinical and technical training.  

Providing care to the Philadelphia region and its western suburbs, Main Line Health is committed to delivering advanced medicine to treat and cure disease, while also playing an important role in prevention strategies and disease management. At its core are four of the region’s most respected acute care hospitals – Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital. Moreover, Main Line Health conducts clinical research in the latest health care innovations and trains physicians and other health care providers to ensure its staff can provide the best, most advanced care to the communities they serve.

“Through this innovative business model, we will have a technology partner who can help us adopt the solutions that will not only help us drive operational efficiency, they will allow us to expand the type of quality care our patients have come to expect,” said Trudy Mazzone, MS, BSRT, (R), System Director, Main Line Health Cardiovascular Services and Co-director, Lankenau Heart Institute.

“By partnering with Philips, we will be able to continue our world-class cardiovascular care system-wide, including fully renovating and installing state-of-the-art Philips equipment to provide advanced cardiovascular and neuro care at Bryn Mawr Hospital and Paoli Hospital,” said William Gray, MD, System Chief, Cardiovascular Diseases, Main Line Health and Co-director, Lankenau Heart Institute. “This will allow us to define a strategy for the future, adopting novel technology as it evolves.”

This long-term strategic partnership will uniquely focus on integrated cardiovascular solutions. As part of the partnership, a dedicated team of Philips solutions architects will work collaboratively with Main Line Health to understand their challenges and develop technology plans around the cardiovascular service line. These technology plans are tailored to their needs with three objectives in mind: clinical, operational, and business model innovation.

Philips brings over a century of experience in healthcare, providing best practices in world-class facility planning and design, intelligent technology implementation, data analytics and IT integration, and education management, as well as workflow and performance optimization.

“Healthcare technology is evolving at a rapid rate and partnering with Main Line Health will allow us to understand patient needs and workflows, map them to the right solutions and help them to deliver on the quadruple aim,” said Vitor Rocha, Market Leader for Philips North America. “Together we can help them keep pace with technology, allowing them to focus on what is most important: providing high-quality care, positive patient outcomes and a superior patient experience for their community.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”